Allspring Global Investments Holdings LLC Sells 3,445 Shares of Novartis AG $NVS

Allspring Global Investments Holdings LLC cut its holdings in Novartis AG (NYSE:NVS) by 3.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 102,595 shares of the company’s stock after selling 3,445 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Novartis were worth $15,911,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. BXM Wealth LLC increased its stake in Novartis by 726.9% in the 4th quarter. BXM Wealth LLC now owns 42,817 shares of the company’s stock worth $5,903,000 after buying an additional 37,639 shares in the last quarter. Spire Wealth Management lifted its position in shares of Novartis by 2,561.0% in the fourth quarter. Spire Wealth Management now owns 38,983 shares of the company’s stock valued at $5,375,000 after acquiring an additional 37,518 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Novartis by 14.4% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 113,737 shares of the company’s stock worth $15,681,000 after acquiring an additional 14,352 shares during the period. HF Advisory Group LLC grew its position in shares of Novartis by 401.0% during the fourth quarter. HF Advisory Group LLC now owns 54,741 shares of the company’s stock worth $7,547,000 after purchasing an additional 43,814 shares in the last quarter. Finally, Concurrent Investment Advisors LLC raised its stake in Novartis by 36.6% during the 4th quarter. Concurrent Investment Advisors LLC now owns 14,815 shares of the company’s stock valued at $2,043,000 after purchasing an additional 3,967 shares during the period. 13.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NVS has been the topic of a number of research analyst reports. Morgan Stanley boosted their price target on Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a report on Thursday, March 26th. Weiss Ratings cut shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research report on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $141.20.

Key Headlines Impacting Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis topped Q2 earnings estimates, posting $2.41 per share versus $2.17 expected, while revenue also came in above forecasts. The beat was driven by strong demand for key drugs and lower-than-expected costs. Novartis earnings report
• Positive Sentiment: The company returned to sales growth in Q2 as newer medicines offset generic pressure, with strength in cancer and multiple sclerosis treatments helping support results. Reuters Q2 profit story
• Positive Sentiment: Management reaffirmed full-year 2026 guidance, which suggests confidence that growth from newer products can continue despite headwinds. Zacks earnings recap
• Neutral Sentiment: Investors are also watching upcoming late-stage trial readouts in the second half of the year, which could influence the stock’s longer-term valuation narrative. Reuters pipeline valuation story
• Negative Sentiment: Ongoing generic competition and a sharp drop in Entresto sales remain major headwinds, and investors may worry about pressure on older blockbusters. Invezz Entresto sales drop story

Novartis Trading Up 2.8%

NVS opened at $153.82 on Wednesday. The stock has a 50-day moving average of $151.61 and a 200 day moving average of $151.88. The company has a current ratio of 0.85, a quick ratio of 0.65 and a debt-to-equity ratio of 0.96. Novartis AG has a 12 month low of $112.34 and a 12 month high of $170.46. The firm has a market cap of $293.51 billion, a P/E ratio of 22.04, a P/E/G ratio of 2.58 and a beta of 0.45.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $14.95 billion for the quarter. Novartis had a return on equity of 38.82% and a net margin of 24.87%. As a group, research analysts forecast that Novartis AG will post 8.75 EPS for the current year.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.